Email updates

Keep up to date with the latest news and content from BMC Neurology and BioMed Central.

Open Access Highly Accessed Research article

Effectiveness of intravenous Dexamethasone versus Propofol for pain relief in the migraine headache: A prospective double blind randomized clinical trial

Hassan Soleimanpour1*, Rouzbeh Rajaei Ghafouri1, Aliakbar Taheraghdam2, Dawood Aghamohammadi3, Sohrab Negargar3, Samad EJ Golzari45 and Mohsen Abbasnezhad6

Author Affiliations

1 Emergency Medicine Department, Tabriz University of Medical Sciences, Daneshgah Street, Tabriz 51664, I.R, IRAN

2 Neurosciences Research Center, Tabriz University of Medical Sciences, Daneshgah Street, Tabriz 51664, I.R, IRAN

3 Anesthesiology and Critical Care Department, Tabriz University of Medical Sciences, Daneshgah Street, Tabriz, 51664, I.R, IRAN

4 Medical Philosophy and History Research Center, Tabriz University of Medical Sciences, Daneshgah Street, Tabriz, 51664, I.R, IRAN

5 Students’ Research Committee, Tabriz University of Medical Sciences, Daneshgah Street, Tabriz, 51664, I.R, IRAN

6 Cardiovascular Research Center, Tabriz University of Medical Sciences, Daneshgah Street, Tabriz 51664, I.R, IRAN

For all author emails, please log on.

BMC Neurology 2012, 12:114  doi:10.1186/1471-2377-12-114

Published: 29 September 2012

Abstract

Background

There are many drugs recommended for pain relief in patients with migraine headache.

Methods

In a prospective double blind randomized clinical trial, 90 patients (age ≥ 18) presenting to Emergency medicine Department with Migraine headache were enrolled in two equal groups. We used intravenous propofol (10 mg every 5–10 minutes to a maximum of 80 mg, slowly) and intravenous dexamethasone (0.15 mg/kg to a maximum of 16 mg, slowly), in group I and II, respectively. Pain explained by patients, based on VAS (Visual Analogue Scale) was recorded at the time of entrance to ED, and after injection. Data were analyzed by paired samples t test, using SPSS 16. P < 0.05 was considered to be statistically significant.

Results

The mean of reported pain (VAS) was 8 ± 1.52 in propofol group and 8.11 ± 1.31 in dexamethasone group at presenting time (P > 0.05). The VAS in propofol group was obviously decreased to 3.08 ± 1.7, 1.87 ± 1.28 and 1.44 ± 1.63 after 10, 20 and 30 minutes of drug injection, respectively. The VAS in dexamethasone group was 5.13 ± 1.47, 3.73 ± 1.81 and 3.06 ± 2 after 10, 20 and 30 minutes of drug injection, respectively. The mean of reported VAS in propofol group was less than dexamethasone group at the above mentioned times (P < 0.05). The reduction of headache in propofol group, also, was very faster than dexamethasone group (P < 0.05). There were no adverse side effects due to administration of both drugs.

Conclusions

Intravenous propofol is an efficacious and safe treatment for patients presenting with Migraine headache to the emergency department.

Trial registration

Clinical Trials IRCT201008122496N4

Keywords:
Migraine headache; Propofol; Dexamethasone; Visual Analogue Scale; Emergency Medicine Department